Actinium Pharmaceuticals, Inc.

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:30:00 16/07/2024 am IST			5-day change	1st Jan Change
7.65 ^USD	+2.68%		+5.96%	+50.59%

01/07	Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2000 Value Index	CI
01/07	Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000 Value Index	CI

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000E Value Index

July 01, 2024

Latest news about Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2000 Value Index	01/07	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000 Value Index	01/07	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2500 Value Index	01/07	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Microcap Value Index	01/07	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index	01/07	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000E Value Index	01/07	CI
Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial	14/06	CI
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	11/06	CI
Actinium Highlights Mutation Data from the Phase 3 Sierra Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development At the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	10/06	CI
Transcript : Actinium Pharmaceuticals, Inc. - Special Call	20/05
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial	15/05	CI
Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target	14/05	MT
Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern	07/05	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	27/04	CI
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting	18/04	CI
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting	01/04	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy	26/03	CI
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating	19/03	MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating	11/12	MT
Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition	11/12	CI
Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer	03/11	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting	02/11	CI
National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc	04/23/04	CI

Chart Actinium Pharmaceuticals, Inc.

Duration

Period

More charts

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Companyâs advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Sector

Biotechnology & Medical Research

Calendar

14/03/2025 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.65 USD

Average target price

25.4 USD

Spread / Average Target

+232.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTINIUM PHARMACEUTICALS, INC.	+50.59%	23Cr
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	13TCr
ARGENX SE	+25.27%	2.77TCr
BIONTECH SE	-20.17%	2.03TCr
GENMAB A/S	-16.64%	1.68TCr
BEIGENE, LTD.	-18.07%	1.56TCr
WUXI APPTEC CO., LTD.	-47.70%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+11.92%	1.48TCr
SAREPTA THERAPEUTICS, INC.	+58.32%	1.44TCr
INSMED INCORPORATED	+149.98%	1.25TCr

Bio Therapeutic Drugs